PLSH
Price
$0.05
Change
-$0.01 (-16.67%)
Updated
Sep 5 closing price
Capitalization
1.11M
STEK
Price
$0.01
Change
-$0.00 (-0.00%)
Updated
Sep 5 closing price
Capitalization
2.05M
Interact to see
Advertisement

PLSH vs STEK

Header iconPLSH vs STEK Comparison
Open Charts PLSH vs STEKBanner chart's image
Panacea Life Sciences Holdings
Price$0.05
Change-$0.01 (-16.67%)
Volume$4.02K
Capitalization1.11M
Stemtech
Price$0.01
Change-$0.00 (-0.00%)
Volume$207.59K
Capitalization2.05M
PLSH vs STEK Comparison Chart in %
Loading...
PLSH
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
STEK
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
PLSH vs. STEK commentary
Sep 07, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is PLSH is a Hold and STEK is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 07, 2025
Stock price -- (PLSH: $0.05 vs. STEK: $0.01)
Brand notoriety: PLSH and STEK are both not notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: PLSH: 42% vs. STEK: 122%
Market capitalization -- PLSH: $1.11M vs. STEK: $2.05M
PLSH [@Pharmaceuticals: Generic] is valued at $1.11M. STEK’s [@Pharmaceuticals: Generic] market capitalization is $2.05M. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $67.95B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $3.94B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

PLSH’s FA Score shows that 1 FA rating(s) are green whileSTEK’s FA Score has 0 green FA rating(s).

  • PLSH’s FA Score: 1 green, 4 red.
  • STEK’s FA Score: 0 green, 5 red.
According to our system of comparison, PLSH is a better buy in the long-term than STEK.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

PLSH’s TA Score shows that 3 TA indicator(s) are bullish while STEK’s TA Score has 4 bullish TA indicator(s).

  • PLSH’s TA Score: 3 bullish, 3 bearish.
  • STEK’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, both PLSH and STEK are a good buy in the short-term.

Price Growth

PLSH (@Pharmaceuticals: Generic) experienced а +2.55% price change this week, while STEK (@Pharmaceuticals: Generic) price change was -18.13% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was +0.10%. For the same industry, the average monthly price growth was +12.13%, and the average quarterly price growth was +87.01%.

Industries' Descriptions

@Pharmaceuticals: Generic (+0.10% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
STEK($2.05M) has a higher market cap than PLSH($1.11M). PLSH YTD gains are higher at: 109.200 vs. STEK (-69.762). PLSH has higher annual earnings (EBITDA): -2.87M vs. STEK (-3.06M). STEK has more cash in the bank: 260K vs. PLSH (243K). STEK has less debt than PLSH: STEK (4.07M) vs PLSH (11.3M). STEK has higher revenues than PLSH: STEK (5.1M) vs PLSH (4.14M).
PLSHSTEKPLSH / STEK
Capitalization1.11M2.05M54%
EBITDA-2.87M-3.06M94%
Gain YTD109.200-69.762-157%
P/E RatioN/AN/A-
Revenue4.14M5.1M81%
Total Cash243K260K93%
Total Debt11.3M4.07M278%
FUNDAMENTALS RATINGS
PLSH vs STEK: Fundamental Ratings
PLSH
STEK
OUTLOOK RATING
1..100
3350
VALUATION
overvalued / fair valued / undervalued
1..100
41
Fair valued
40
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
10097
PRICE GROWTH RATING
1..100
4597
P/E GROWTH RATING
1..100
2993
SEASONALITY SCORE
1..100
5043

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

STEK's Valuation (40) in the null industry is in the same range as PLSH (41). This means that STEK’s stock grew similarly to PLSH’s over the last 12 months.

STEK's Profit vs Risk Rating (100) in the null industry is in the same range as PLSH (100). This means that STEK’s stock grew similarly to PLSH’s over the last 12 months.

STEK's SMR Rating (97) in the null industry is in the same range as PLSH (100). This means that STEK’s stock grew similarly to PLSH’s over the last 12 months.

PLSH's Price Growth Rating (45) in the null industry is somewhat better than the same rating for STEK (97). This means that PLSH’s stock grew somewhat faster than STEK’s over the last 12 months.

PLSH's P/E Growth Rating (29) in the null industry is somewhat better than the same rating for STEK (93). This means that PLSH’s stock grew somewhat faster than STEK’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
PLSHSTEK
RSI
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
74%
Bullish Trend 2 days ago
84%
Momentum
ODDS (%)
Bullish Trend 2 days ago
76%
Bearish Trend 2 days ago
90%
MACD
ODDS (%)
Bullish Trend 2 days ago
70%
Bearish Trend 2 days ago
90%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
71%
Bearish Trend 2 days ago
90%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
86%
Bearish Trend 2 days ago
90%
Advances
ODDS (%)
N/A
Bullish Trend 20 days ago
78%
Declines
ODDS (%)
Bearish Trend about 1 month ago
86%
Bearish Trend 4 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
90%
Aroon
ODDS (%)
N/A
Bearish Trend 2 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
PLSH
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
STEK
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
PRLD1.230.09
+7.89%
Prelude Therapeutics
QMMM7.610.49
+6.88%
QMMM Holdings Ltd
QDEL28.680.89
+3.20%
QuidelOrtho Corp
AUR5.730.14
+2.50%
Aurora Innovation
SMX1.41-0.10
-6.62%
SMX (Security Matters) Public Limited Company

STEK and

Correlation & Price change

A.I.dvisor tells us that STEK and CNADF have been poorly correlated (+25% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that STEK and CNADF's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To STEK
1D Price
Change %
STEK100%
-3.45%
CNADF - STEK
25%
Poorly correlated
N/A
BFRI - STEK
12%
Poorly correlated
+0.64%
HLNCF - STEK
11%
Poorly correlated
-0.61%
PLSH - STEK
8%
Poorly correlated
-18.28%
EAPIF - STEK
6%
Poorly correlated
N/A
More